outcomes of all-cause and cardiovascular death. Results: Follow-up time was 7.3 ± 1.9 years. By BIS2, 42 and 11% had eGFR <60 and <45, respectively, compared to CKD-EPI cr (23 and 6%), CKD-EPI cysc (36 and 13%) and CKD-EPI cr,cysc (28 and 8%). BIS2 eGFR <45 was associated with twofold higher rate of all-cause mortality when compared to eGFR ≥ 75 after multivariate adjustment (HR 2.1, 95% CI 1.5-2.8). Results were similar for CKD-EPI cr,cysc <45 (HR 2.1, 95% CI 1.6-2.7) and CKD-EPI cysc <45 (HR 2.1, 95% CI 1.7-2.7) and weaker for CKD-EPI cr <45 (HR 1.5, 95% CI 1.2-2.0). In NRI analyses, when compared to CKD-EPI cr,cysc , both BIS2 and CKD-EPI cr equations more often misclassified participants with respect to mortality. We found similar results for cardiovascular death. Conclusion: The BIS2 did not outperform and the CKD-EPI cr was inferior to the cystatin C-based CKD-EPI equations to predict death in this cohort of older men. Thus, the cystatin C-based CKD-EPI equations are the formulae of choice to predict death in community-dwelling older men.
Introduction
Nearly 1 in 4 Americans over 60 years of age in the United States have chronic kidney disease (CKD) defined by an estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73 m 2 [1] . Older adults with CKD suffer high rates of morbidity and mortality, in excess of what is attributable to their age and comorbid conditions [2] [3] [4] . Studies of mortality risk among older adults suggest that CKD is an independent risk factor for death, including death due to cardiovascular events [4] . However, the level of renal function at which this increased risk begins is unclear, likely due to challenges in measurement of renal function in aged populations [4] . Specifically, among healthy older adults, the insensitivity of serum creatinine (SCr)-based measures to predict death and the lack of eGFR formulae developed for this population may lead to inaccurate risk estimates [5] .
To address the insensitivity of SCr-based measures of GFR, newer equations have incorporated serum cystatin-C (SCysc) alone or in combination with SCr in an effort to overcome some of the limitations of SCr-based measures [5] . The Chronic Kidney Disease Epidemiology (CKD-EPI) collaboration equations were developed using a pooled sample of participants from various studies to represent a range of ages and renal function as measured using SCysc and/or SCr [5] . Findings from the CKD-EPI collaboration suggest that among older adults, renal function as estimated by SCysc-or SCr/SCysc-based equations are more sensitive predictors of mortality than when estimated using SCr-based formulae [6] . However, questions remain about the predictive validity of these equations in the aged population as the mean age of the CKD-EPI cohorts was in the range 47-51 with only 13% of subjects over 65 years [5] .
Recently, in an effort to develop and validate an estimating equation in an older cohort, investigators in the Berlin Initiative Study (BIS) developed 2 novel equations, the BIS1 (SCr-based) and BIS2 (SCr and SCyscbased) equations, using as their gold standard a direct measurement of GFR in a random community-based sample of 570 men and women over age 70 enrolled in a large health insurance program [7] . This study reported that the BIS2 equation yielded the best estimate of measured GFR (mGFR) when compared to Modification of Diet and Renal Disease, Cockroft-Gault, CKD-EPI cr , and the 2008 CKD-EPI equations based upon SCysc (with and without age, gender adjustment) or combination of SCysc and SCr [7, 8] . However, no study to date has compared the ability of the BIS2 equation to predict risk of all-cause and cardiovascular mortality in communitydwelling older adults to that of other estimating equations [7] . Therefore, using data collected in prospective multicenter cohort study of community-dwelling older men aged 67 years and older, we compared the ability of the BIS2 equation and other standard estimating equations used clinically and in research to that of the CKD-EPI cr,cysc equation to predict all-cause and cardiovascular mortality.
Subjects and Methods

Participants
From 2000 through 2002, 5,994 men who were ≥ 65 years were recruited for participation in the baseline examination of the Osteoporotic Fractures in Men (MrOS) Study, the parent cohort for the MrOS Sleep Study [9, 10] . The enrollment criteria were designed to recruit a cohort that represented characteristics of community-dwelling older men residing in the United States [9, 10] . Men were recruited from population-based listings in 6 regions (Birmingham, Alabama; Minneapolis, Minnesota; Palo Alto, California; the Monongahela Valley near Pittsburgh, Pennsylvania; Portland, Oregon; and San Diego, California) [9, 10] . Men with a history of bilateral hip replacement, men who were unable to walk without the assistance of another person and men with a medical condition (in the judgment of the investigator) that would result in imminent death were excluded [9, 10] .
Between December 2003 and March 2005, a total of 3,135 men from MrOS were recruited for participation in the MrOS Sleep Study as part of an ongoing prospective study of consequences of sleep disorders in this population. Of the 3,135 men enrolled in MrOS Sleep, 3,034 participants had serum from the MrOS Sleep visit available for measurement of renal function. Of these men, 40 men were missing data on vital status, leaving 2,994 men in the final analytical cohort.
All men provided written informed consent, and the study was approved by the Institutional Review Board at each site.
Measurement of Renal Function Biomarkers
Measurement of renal function biomarkers was performed on previously frozen (-70 ° C) stored serum samples from the MrOS Sleep visit; SCr and SCysc were measured from the same sample and freeze-thaw cycle between July 31, 2013 and August 23, 2013. SCr was analyzed using the Roche Modular P chemistry analyzer (Enzymatic/Roche Diagnostics Corp., Indianapolis, Ind., USA). This assay is calibrated to be isotope dilution mass spectrometry traceable. SCysc was measured using the Roche Modular P chemistry analyzer (Turbidimetric/Gentian AS, Moss, Norway). This assay is calibrated to the international cystatin C reference material ERM-DA471/ IFCC. Both assays were performed at the Fairview University Medical Center Clinical Laboratory, Minneapolis, Minn., USA. The interassay coefficient of variation (CV) for SCr is 3.7% at 0.82 mg/dl and 2.3% at 3.62 mg/dl. For SCysc the inter-assay CV is 4.1% at 0.94 mg/l and 2.8% at 3.29 mg/l. We estimated GFR using the CKD-EPI cr , CKD-EPI cysc CKD-EPI cr,cysc and BIS2 equations as detailed in the online supplementary appendix 
Other Measurements
Candidate variables included in our analysis were collected primarily from the baseline MrOS Sleep visit during [2003] [2004] [2005] . Race/ethnicity and education were determined from the baseline MrOS visit. Variables used in this study included age and race/ ethnicity, where race/ethnicity was defined as white, black or other (defined as Asian, Hispanic, Pacific Islander, American Indian or more than one race); body mass index (BMI, kg/m 2 ) as a measure of obesity as well as measures of lean body mass (total and appendicular lean muscle mass as determined by dual energy Xray absorptiometry, Hologic 4500 scanners, Waltham, Mass., USA); tobacco and alcohol use; self-reported health status based upon SF-12 questionnaire [12] ; and medical history including hypertension (HTN: self-report or any anti-hypertensive medication use), diabetes mellitus (DM: self-report or any hypoglycemic medication use), self-reported peripheral vascular disease, self-reported coronary heart disease (CHD: myocardial infarction, angina, bypass or angioplasty), self-reported history of congestive heart failure (CHF) or self-reported history of cerebrovascular disease (history of stroke).
Statistical Analysis
Our primary analysis compared the performance of the BIS2 equation with the CKD-EPI cr,cysc equation to predict mortality. Thus, we examined baseline characteristics and potential confounders of the association between renal function and mortality across eGFR categories ( ≥ 75, 60-74, 45-59 and <45 ml/min/1.73 m 2 ; henceforth, eGFR units are removed for ease of reading) defined by the CKD-EPI cr,cysc equation. Statistical differences across the eGFR category were calculated using chi-square and analysis of variance tests for categorical and continuous variables, respectively. We also compared the prevalence of participants in each eGFR category using each of the 4 estimating equations with a chi-square test. Nonparametric kernel estimation densities of eGFR were plotted for each of the 4 estimating equations.
We determined all-cause and cardiovascular mortality rate (deaths/1,000 person-years) during an average of 7.3 years of follow-up by category of baseline eGFR for each estimating equation. Cox proportional hazards regression was used to determine hazard ratios for death. Based upon factors determined a priori with clinical relevance to be potential confounders of the association between renal function and mortality (age, race/ethnicity, BMI, DM, HTN) and other factors that were associated with both predictor and outcomes, we present the following models: (1) an unadjusted model (site only); (2) a base model, further adjusted for age, race/ethnicity and BMI; and (3) a final model, further adjusted for HTN, DM, CHF, CHD, and stroke.
Finally, in order to determine how all-cause and cardiovascular mortality for each eGFR category changed depending upon the estimating equation used, we calculated a metric comparable to the net reclassification improvement (NRI) for each formula compared to the CKD-EPI cr,cysc (online suppl. appendix table 2 for NRI formulae) [13] . A positive NRI, which is the total for the estimating equation evaluated means that the equation more often appropriately reclassifies to a higher eGFR (better function) than those participants who lived and/or reclassifies to a lower eGFR (worsefunction) those who died when compared to the referent equation (CKD-EPI cr,cysc ). We also present a category-free NRI, which defines reclassification as 1 unit change in eGFR [14] . The categoryfree NRI allows us to provide estimates that may be more comparable across studies including the eGFR categories we have chosen [14] .
In secondary analyses, we repeated all of the above analyses expressing eGFR in quartiles. All significance levels reported were two sided and all analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, N.C., USA).
Results
Baseline eGFR and Characteristics
Fewer (17%) participants were categorized as eGFR ≥ 75 by BIS2 eGFR in contrast to 44, 36, and 40% for the CKD-EPI cr , CKD-EPI cysc and CKD-EPI cr,cysc respectively (p < 0.001 for all pairwise comparisons; table 1 ). The BIS2 equation identified a larger proportion of participants as having eGFR <60 (42%) compared to 23, 36, and 28% with eGFR <60 for the CKD-EPI cr , CKD-EPI cysc and CKD-EPI cr,cysc respectively. The overrepresentation of eGFR <60 by BIS2 was largely due to a higher prevalence Men with lower CKD-EPI cr,cysc eGFR or worse renal function were on average older, had higher BMI and lower total and appendicular lean body mass ( table 2 ; see similar tables by BIS2, CKD-EPI cysc , and CKD-EPI cr in online suppl. appendix tables 3-5). Also, men with lower CKD-EPI cr,cysc eGFR reported worse health status and had more HTN, DM, CHD, CHF, peripheral vascular disease and stroke.
eGFR and Mortality
During the average follow-up of 7.3 ± 1.9 years, 751 (25%) men died. Overall, in unadjusted analyses, lower category of eGFR (worse renal function) using either CKD-EPI equation was associated with a graded increase in mortality ( table 3 ) . Participants with CKD-EPI cr,cysc <45, 45-59, and 60-74 were 4.4, 2.2, and 1.5 times more likely to die, respectively, than those with CKD-EPI cr,cysc ≥ 75 (p-trend < 0.001). For those with eGFR <45 and 45-59 this association persisted despite multivariate adjustment. CKD-EPI cysc eGFR results were similar to those for CKD-EPI cr,cysc ( table 3 ) . In unadjusted analyses, BIS2 (p-trend < 0.001). After multivariate adjustment, this association was attenuated such that only eGFR <45 was associated with a statistically significant increased risk of death, though point estimates were similar to CKD-EPI equations. Finally, the hazard ratios for death by CKD-EPI cr eGFR category and mortality followed a similar trend to the BIS2 and CKD-EPI analyses, though the point estimates were less robust (HR for death for CKD-EPI cr eGFR <45 vs. ≥ 75 1.5, p-trend = 0.01). When cardiovascular mortality was the outcome, results were similar to those for all-cause mortality except that the point estimates for CKD-EPI cr eGFR as a predictor of cardiovascular death were comparable to the other 3 equations (online suppl. appendix table 6). In sensitivity analyses, when eGFR was categorized in quartiles instead of categories, we found overall similar results for the association between eGFR and mortality (online suppl. appendix tables 7 and 8).
Finally, in order to determine the ability of the BIS2 formula to appropriately re-classify participants for risk of all-cause and cardiovascular death when compared to the CKD-EPI EPI cr,cysc formula, we calculated both categorybased and category-free NRI ( table 4 ). For each CKD-EPI cr,cysc category, the BIS2 either made no change in category or reclassified participants down to a lower eGFR regardless of event status, except for one participant. For those who died (experienced an event), the recategorization to a lower eGFR by BIS2 reflected an appropriate and statistically significant reclassification. However, for those who did not die (no event), the recategorization to a lower eGFR by BIS2 (except for one participant) reflected an inappropriate and statistically significant reclassification. Because overall BIS2 reclassified more participants to lower eGFR inappropriately for their vital status, the net combination of the NRI for events and non-events was negative when compared to CKD-EPI cr,cysc ; however, the net NRI was not statistically different from zero. A negative overall NRI value means that the BIS2 compared to CKD- EPI cr,cysc formula reclassified participants into a risk category (or eGFR category in this case) less appropriately for the outcome (death vs. no death). Results of category-free analyses based upon 1 change in eGFR were similar in direction to the category-based NRI for the comparison between CKD-EPI cr,cysc and BIS2 but the point estimate was greater in magnitude and was statistically significant ( table 4 ). Results of similar NRI comparisons between CKD-EPI cysc vs. CKD-EPI cr,cysc found that CKD-EPI cysc led to more appropriate reclassification of eGFR for risk of death than inappropriate classification, though small in magnitude. In contrast, the CKD-EPI cr equation led to a greater proportion with inappropriate reclassification for their risk of death than appropriate reclassification when compared to CKD-EPI cr,cysc . We found similar results when cardiovascular mortality was the outcome ( table 4 ).
Discussion
We found that among community-dwelling older men, the BIS2 eGFR formula identified a higher proportion of participants as having CKD when compared to the CKD-EPI cr,cysc , CKD-EPI cysc , and CKD-EPI cr eGFR equations. This was largely due to identification of a higher proportion of participants with eGFR 45-59. In general, lower eGFR was associated with higher mortality, but the CKD-EPI equations were more sensitive and robust predictors of death than the BIS2 and CKD-EPI cr equations. Finally, when compared to CKD-EPI cr,cysc , both the BIS2 and CKD-EPI cr equations led to more inappropriate classification of participants with respect to mortality risk. For BIS2, this was driven by recategorization of participants who did not die to a lower eGFR. Taken together, our findings suggest that the BIS2 equation did not outperform and the CKD-EPI cr equation was inferior to the cystatin-C-based CKD-EPI equations to predict death among these community-dwelling older men. The higher prevalence of eGFR <60 by the BIS2 (42%) is consistent with what is reported in the literature for BIS2 eGFR and mGFR in community-dwelling older adults [7, 15, 16] . However, the BIS2 equation did not perform as well to predict death when compared to the SCysc-based CKD-EPI equations in this cohort of healthy older men. The first 3 explanations we present rest upon the assumption that the mortality risk predicted by eGFR is a direct result of the impact of renal function mGFR. First, in internal validation against iohexol mGFR, BIS2 performed better than the SCysc-based CKD-EPI and CKD-EPI cr with respect to bias, precision and accuracy [7] . However, recent studies have shown variable performance upon external validation [15, 17, 18] . For example, in a study of 805 community-dwelling, older Icelandic men and women with mean iohexol GFR 62.4 ± 16.5, both the BIS2 and the SCr-based BIS equations had greater bias but similar precision and accuracy when compared to SCysc and SCr-based CKD-EPI equations [15] . In fact, both BIS equations had negative bias with respect to mGFR across all levels of renal function, but this was greater at higher mGFR [15] . This finding was echoed in another study of 394 Caucasian men and women with median iohexol mGFR 53 (IQR 7.2-100.9) and another of 95 Brazilian men and women with mean iohexol mGFR 55 ± 15 [17, 18] . The negative bias observed in these studies may in part explain the inappropriate reclassification to a lower eGFR by BIS2 compared to CKD-EPI cr,cysc with respect to risk of death. A second explanation for our findings is that, despite similarities in prevalence of CKD between MrOS Sleep and the BIS, other differences between our cohort and the BIS cohort affected the performance of BIS2 to predict death in MrOS Sleep. Indeed, the BIS cohort was only 58% male, while our cohort is entirely male [7] . In addition, our cohort had less DM and HTN compared to the BIS cohort (for MrOS vs. BIS 13 vs. 27% for DM and 63 vs. 78% for HTN) [7] . However, both cohorts consisted of community-dwelling adults who were entirely (BIS) or largely (MrOS Sleep) Caucasian with a mean age in the range 76-78 [7] . In contrast, the cohorts used to develop the CKD-EPI equations were younger (mean age 47 ± 15), more racially diverse with more DM and a greater spectrum of renal function than both the BIS and MrOS cohorts [5, 7] . Nevertheless, the performance of the SCysc-based CKD-EPI equations to predict mortality was superior to BIS2 in this cohort of older community-dwelling men. This suggests that differences between MrOS and the BIS participants are less likely to explain our findings. Third, it may also be that our choice of eGFR cutpoints for the categories may have somehow biased our findings against the BIS2 equation. However, re-examination of our data using eGFR in quartiles and category-free NRI yielded similar results suggesting that the selection of clinically relevant cutpoints for eGFR categories played a minimal role in our findings. Finally, the ability of each eGFR equation to predict death may be related to the prognostic value of the surrogate markers beyond that of mGFR. SCr is well known to reflect muscle mass [15] . In older adults, muscle mass reflects better health status and lower risk, but the resultant higher SCr results in lower eGFR and inappropriate allocation to a higher risk category. While SCysc may improve upon the limitations of SCr, it too may represent putative non-GFR determinants such as inflammation and fat mass or others that are as yet unknown [19] . Regardless, our primary focus was to compare the BIS2 equation, which incorporates both SCysc and SCr to CKD-EPI cr,cysc . But for the absence of a race consideration by BIS2 that would be of little impact in the MrOS cohort of 90% Caucasian participants, both equations contain similar markers and considerations: SCysc and SCr, age and gender. Thus, differences observed in performance were less likely related to non-GFR determinants of surrogate markers used but rather related to characteristics of the formula used.
Our findings have important clinical and research implications. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines 2012 recommends use of SCysc-based eGFR when the eGFR is 45-59 and there is no other evidence of renal damage such as albuminuria [20] . They further recommend the use of the CKD-EPI equations or other equations that incorporate both SCr and SCysc if they are more accurate for a given population [20] . Community-dwelling older adults constitute a considerable proportion of eGFR cr 45-59 without evidence of renal damage and thus would benefit from SCysc measurement for confirmation of CKD [20] . Furthermore, the 2014 Kidney Disease Outcomes Quality Initiative commentary on KDIGO suggested that SCyscbased measures improve upon SCr-based measures with respect to risk stratification [21] . It was therefore of great interest when the BIS provided the first SCyscbased equations developed specifically for communitydwelling older adults providing a potentially more appropriate equation for risk stratification in this popula-
